{"id":"optimised-rituximab-schedule","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the CD20 antigen on the surface of B cells, rituximab triggers cell-mediated cytotoxicity and induces apoptosis, leading to a reduction in B cell count and activity. This mechanism is particularly effective in treating B cell-related disorders such as non-Hodgkin lymphoma and rheumatoid arthritis.","oneSentence":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:32.968Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin lymphoma"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT01478542","phase":"PHASE3","title":"OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2011-11","conditions":"CD20+ Aggressive B-Cell Lymphoma","enrollment":1152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"optimised rituximab-schedule","genericName":"optimised rituximab-schedule","companyName":"Universität des Saarlandes","companyId":"universit-t-des-saarlandes","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Non-Hodgkin lymphoma, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}